Risk of major vascular events in patients without traditional risk factors after transient ischemic attack or minor ischemic stroke: An international prospective cohort
The 5-year risk of MACE was lower in patients without TRFs than those with TRFs, although a certain level of risk persisted in the absence of TRFs. The most significant predictor of MACE in patients without TRFs was arterial stenosis.
Authors
- Pierre Amarenco (ORCID: https://orcid.org/0000-0002-3842-1236)
- Gregory W. Albers (ORCID: https://orcid.org/0000-0003-0263-4632)
- Shinichiro Uchiyama (ORCID: https://orcid.org/0000-0002-6280-8190)
- Hubert Charles (ORCID: https://orcid.org/0000-0002-0809-4705)
- Geoffrey Alan Donnan (ORCID: https://orcid.org/0000-0001-6324-3403)
- Kazuo Minematsu (ORCID: https://orcid.org/0000-0003-3307-2708)
- Louis R. Caplan (ORCID: https://orcid.org/0000-0002-7507-9521)
- Ka Sing Wong (ORCID: https://orcid.org/0000-0002-2031-9866)
- José Manuel Ferro (ORCID: https://orcid.org/0000-0002-2343-9097)
- Takao Hoshino (ORCID: https://orcid.org/0000-0002-2477-9755)
- Marie-Laure Meledje
- Michael G. Hennerici
- Peter M. Rothwell
- Carlos A. Molina
Institutions
- Universitat Autònoma de Barcelona (ES)
- Beth Israel Deaconess Medical Center (US)
- The Royal Melbourne Hospital (AU)
- University of Lisbon (PT)
- The University of Melbourne (AU)
- Chinese University of Hong Kong (HK)
- Heidelberg University (DE)
- University of Oxford (GB)
- National Cerebral and Cardiovascular Center (JP)
- Prince of Wales Hospital (CN)
- Oxford Centre for Computational Neuroscience (GB)
- Tokyo Women's Medical University (JP)
- Stanford Medicine (US)
- Hôpital Bichat-Claude-Bernard (FR)
- Sanno Medical Center (JP)
- International University of Health and Welfare (JP)
- Stanford University (US)
Publication Details
- Journal
- European Stroke Journal
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1177/23969873241300071
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Japan Cardiovascular Research Foundation